

**daratumumab 16 mg/kg -
cyclophosphamide 300 -
bortezomib 1.5 -
dexamethasone 20 mg**

Regimen: Cycles 3-6 (Part I)

ARIA Protocol Name: Daratumumab IV CyBorD (age and comorbidities)

Adult Chemotherapy - Hematology Oncology

Multiple Myeloma



CC4570 0267 09 2022

Name: _____

HCN: _____

Date of Birth: _____

Allergies:

No Known

Date: DD/MONTH/YYYY

Planned Administration Date: DD/MONTH/YYYY

Cycle _____ of _____ **Cycle Duration: 28 days**

Date of previous cycle: DD/MONTH/YYYY

MAY PROCEED WITH DOSES AS WRITTEN IF:

- ANC **greater than or equal to** $1 \times 10^9/L$ and platelets **greater than or equal to** $80 \times 10^9/L$, otherwise notify Hematologist.
- LFTs and Bilirubin assessed.
- Creatinine clearance assessed.
- Neurotoxicity assessment completed

PREMEDICATIONS (FOR HOSPITAL PHARMACY):

- 60 minutes prior to daratumumab: diphenhydrAMINE 50 mg PO** on day 1 and 15
- 60 minutes prior to daratumumab: acetaminophen 650 mg PO** on day 1 and 15
- Other: _____

HYDRATION/SUPPORTIVE CARE (FOR COMMUNITY PHARMACY):

- acyclovir 800 mg PO** once daily until one month post completion of daratumumab/bortezomib treatment
- metoclopramide 10-20 mg PO** every 4 hours as needed
- Other: _____

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: _____ Date: DD/MONTH/YYYY Time: _____

Authorized Prescriber's Signature: _____ ID #: _____

Nurse's Name: _____ Date: DD/MONTH/YYYY Time: _____

Nurse's Signature: _____

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.



Doctor's Order Sheet

**daratumumab 16 mg/kg -
cyclophosphamide 300 -
bortezomib 1.5 -
dexamethasone 40 mg**

Regimen: Cycles 3-6 (Part II)

ARIA Protocol Name: Daratumumab IV CyBorD (age and comorbidities)

Adult Chemotherapy - Hematology Oncology

Multiple Myeloma



CC4570 0267 09 2022

Weight: _____ kg Height: _____ cm Body Surface Area (BSA) = _____

CHEMOTHERAPY (FOR HOSPITAL PHARMACY):

bortezomib 1.5 mg/m² X BSA = _____ mg

Dose modification: **bortezomib 1.5 mg/m² X BSA - _____ % = _____ mg**

SC on day 1, 8, 15 and 22

daratumumab 16 mg/kg X weight (kg) = _____ mg

Dose modification: **daratumumab 16 mg/kg X weight (kg) - _____ % = _____ mg**

IV in 500 mL normal saline on day 1 and 15 (1000 mL if infusion reaction during last daratumumab infusion)

Observe patient for 30 minutes after infusion (observation not required after 3 treatments with no reaction)

If no reaction in the previous infusion or reaction is Grade 2 or less: Start infusion at 200 mL/hr. If no reaction after 30 minutes, infuse the remainder at 450 mL/hr

If reaction in the previous infusion is Grade 3: Start infusion at 100 mL/hr. If no reactions after 60 minutes, increase by 50 mL/hr every 60 minutes until maximum of 200 mL/hr

CHEMOTHERAPY (FOR COMMUNITY PHARMACY):

dexamethasone 20 mg PO once daily in the morning on day 1, 8, 15 and 22 (60 minutes pre daratumumab on day 1 and 15)

cyclophosphamide 300 mg/m² X BSA = _____ mg

Dose modification: **cyclophosphamide 300 mg/m² X BSA - _____ % = _____ mg**

PO on day 1, 8, 15 and 22

This prescription is NOT eligible for medication management by a pharmacist

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: _____ Date: DD/MONTH/YYYY Time: _____

Authorized Prescriber's Signature: _____ ID #: _____

Nurse's Name: _____ Date: DD/MONTH/YYYY Time: _____

Nurse's Signature: _____

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.